Genetic Technologies Limited announce the appointment of experienced Chief Financial Officer, Mr. Tony Di Pietro. Tony will also be appointed as Company Secretary upon his arrival. Mr. Di Pietro is a Chartered Accountant and an Associate of the Governance Institute Australia with 18 years Biotechnology industry experience.

Most recently Tony was at INOVIQ Ltd. where he oversaw the merger between two ASX listed companies BARD1 Life Sciences Ltd. and Sienna Cancer Diagnostics Ltd. Tony joins GTG at a time of significant expansion in geneType brand internationally and an increasing presence in the US and European markets. The Company's direct-to-consumer EasyDNA and AffinityDNA brands continue to capitalize on growth opportunities in the US, Europe, and Asia.